Ulrike Haus

Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours

Andreas Helisch, GregorJ. F�rster, Helmut Reber et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2004 · 129 citations

Glioma, Medicine, Pharmacology +9

Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells

Oliver Treeck, Birgit Wackwitz, Ulrike Haus et al. · Gynecologic Oncology · 2006 · 96 citations

Oncology, Medicine, Cell Death +10

Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia: Results of a Prospective Phase II Open-Label Multicenter Study

Donald Bunjes, W. Siegert, Rainer Schwerdtfeger et al. · Journal of Clinical Oncology · 2005 · 93 citations · Full text

Antiinflammatory effects of 5‐HT₃receptor antagonists in lipopolysaccharide‐stimulated primary human monocytes

BL Fiebich, RS Akundi, K Lieb et al. · Scandinavian Journal of Rheumatology · 2004 · 79 citations

Immunology, Receptor Antagonists, Cell Death +16

Physiology and pathophysiology of the 5‐HT₃receptor

L. Färber, Ulrike Haus, M. Späth et al. · Scandinavian Journal of Rheumatology · 2004 · 75 citations

Synaptic Transmission, Neurotransmitter, Receptor Antagonists +25